Latest
 
  • All Share : 52797.58
    DOWN -0.91%
    Top40 - (Tradeable) : 45916.48
    DOWN -1.02%
    Financial 15 : 15104.54
    DOWN -0.34%
    Industrial 25 : 70311.61
    DOWN -0.65%
    Resource 10 : 31313.57
    DOWN -2.79%

  • ZAR/USD : 13.8787
    DOWN -1.94%
    ZAR/GBP : 18.3403
    DOWN -1.32%
    ZAR/EUR : 15.52
    DOWN -1.00%
    ZAR/JPY : 0.1356
    UP 1.27%
    ZAR/AUD : 10.5485
    DOWN -0.74%

  • Gold US$/oz : 1350.4
    UP 1.18%
    Platinum US$/oz : 1147
    UP 1.41%
    Silver US$/oz : 20.29
    UP 0.90%
    Palladium US$/oz : 709
    UP 1.87%
    Brent Crude : 42.46
    DOWN -0.35%

  • All data is delayed by 15 min. Data supplied by Profile Data
    Hover cursor over this ticker to pause.

Sat Jul 30 22:46:56 CAT 2016

Dutch dope busts price of minty ganja gum

Reuters | 05 January, 2016 00:39
That spray, Sativex, is already approved in 27 countries - though not in the US, where cannabis remains prohibited under federal law. File photo
Image by: STEVE DIPAOLA / REUTERS

AXIM Biotechnologies, a small, Manhattan-based company with ties to the Netherlands, says it has a trump card in its quest to develop a cannabis-based chewing gum to ease the symptoms of multiple sclerosis.

The company says it will be able to price its gum cheaper than a major competitor after securing a "significant" discount on cannabis made available by the Dutch government.

To be sure, AXIM has a long way to go before its Medchew Rx gum - still in development - will be a viable alternative to an under-the-tongue spray developed by GW Pharmaceuticals.

That spray, Sativex, is already approved in 27 countries - though not in the US, where cannabis remains prohibited under federal law.

Provided treatment is regulated, cannabis could be therapeutic for MS patients, said Paul Wright, chairman of neurology at North Shore University Hospital in Manhasset, New York.

"I do believe that there's a role for it," he said, "but I am fearful of the potential for abuse."

Lekhram Changoer, AXIM's Dutch chief technology officer, said the company would be able to pass on the discount from its Dutch-sourced cannabis to customers.

He declined to estimate the price.

A typical British patient takes four sprays of Sativex daily at a cost of about $8.24 (about R130).

AXIM, which started out in the organic waste business before reinventing itself last year, hopes its mint-flavoured gum will be on sale in the US as early as next year pending Food and Drug Administration approval.

SHARE YOUR OPINION

If you have an opinion you would like to share on this article, please send us an e-mail to the Times LIVE iLIVE team. In the mean time, click here to view the Times LIVE iLIVE section.